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Bisphosphonate-associated osteonecrosis of the jaws (BRONJ) may have signiﬁcant morbidities ranging
from minimal discomfort to signiﬁcant loss of function. We report a case of jaw osteonecrosis resulting
from long-term use of bisphosphonate. An 83-year-old female, a long-term user of alendronate, devel-
oped jaw osteonecrosis without a history of recent dental extraction. Facial bone computed tomography
of the patient showed a destructive osteolytic change of the whole right mandible bone with adjacent
soft tissue swelling. After surgical debridement, antibiotic treatment, and discontinuation of alendronate,
the patient recovered very well. Although uncommon, BRONJ has gained extensive attentions. Physicians
should be aware of the possibility of BRONJ among long-term bisphosphonate users, and a collaboration
of clinical pharmacist may be helpful in early detection.
Copyright  2010, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
Osteoporosis is common in the elderly population and a signiﬁ-
cant burden in termsof impairedqualityof life.1 It is estimated that 10
million people aged above 50 years in the United States have osteo-
porosis.2 Oral or intravenous bisphosphonates are common phar-
macologic agents to treat osteoporosis. Todate,more than190million
prescriptions for oral bisphosphonates have been dispensed world-
wide,3 and long-acting bisphosphonates have become the main-
stream of osteoporosis treatment.4,5 In addition to the antiresorptive
effect of bisphosphonate, the potential of osteoclast-mediated bone
resorption in treating other diseases has gained more and more
attention. Although bisphosphonate is generally agreed to be safe,
increasing body of evidences suggest that long-term bisphosphonate
use may be associated with an unusual conditiondjaw osteonec-
rosis.6,7 Herein, we report a case of long-term bisphosphonate user
who developed unexplained jaw osteonecrosis and to evaluate the
treatment response.
2. Case report
An 81-year-old lady who had history of bronchial asthma,
hypertension, gastric ulcer, and osteoporosis took alendronateMedicine, China Medical
0402, Taiwan.
in).
linical Gerontology & Geriatrics. P(70 mg/wk) for two years in a community hospital in Taiwan.
However, she felt persistent pain in the right cheek for the past six
months, so she visited geriatric outpatient department for this
condition and polypharmacy. The patient stated that she had
persistent right cheek pain for sixmonths and the pain still remained
despite avisit to adentist. Shewassuggested tovisit a tertiarymedical
center for further opinion and treatment. However, the development
of gastric ulcer delayed her visit for the pain of her right cheek. The
pain deteriorated progressively, which caused her difﬁculties inFig. 1. Raw bone exposure at lower right mandible area with purulent pus discharge,
about 3.0 1.5 cm.
ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Fig. 2. Destructive osteolytic change in the whole right mandible bone with adjacent soft tissue swelling.
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of this aggravated cheek pain and the burden of polypharmacy.
Physical examinations revealed painful swelling of the right cheek
with limited mouth opening, bone exposure at the lower right area
with purulent discharge (about 3.01.5 cm in size and #27 elonga-
tion ulcer area) (Fig. 1). Dental panoramic radiography was done
showing a diffuse osteolysis of the right mandibular body and
a sequestrum near the alveolar crest. The clinical impressionwas jaw
osteonecrosis with secondary infection, which may be associated
with long-term use of bisphosphonate. Facial bone computed
tomographywasdonerevealingadestructiveosteolytic change in the
whole rightmandible bonewith adjacent soft tissue swelling (Fig. 2).
Throughout thewhole course of treatment, therewas neither trauma
nor denture implant nor previous dental surgery, so the patient was
admitted under impression of bisphosphonate-associated osteonec-
rosis of the jaws (BRONJ) with secondary infection. During her
hospital admission, surgical debridement, antibiotic use, and
discontinuation of alendronatewere done, and the patient recovered
well from the BRONJ.
3. Discussion
Bisphosphonates are potent inhibitors of osteoclasts, whichmay
unavoidably retard the skeletal repair processes associated with
trauma. It has been hypothesized that the constant use of jaw
bones may result in minor traumas, and the associated continuing
bone remodeling is the cause of a preferential accumulation
of bisphosphonates and leading to osteonecrosis.8,9 The incidence
of BRONJ in long-term bisphosphonate users ranged from
1%e10%.10e13 Because osteoporosis is an age-related disease, the
prevalence and incidence rise with older age. Therefore, long-term
use of bisphosphonatemay be a commonphenomenon in the aging
population. Two theories have been proposed to clarify the path-
ogenesis of BRONJ. One focused on the bisphosphonate-induced
osteoclast inhibition and the other favors the antiangiogenic
mechanisms to be the contributing factor.8 In most cases, the
development of osteonecrosis of the jaws among those long-term
bisphosphonate users is associated with traumas, predominantly
dental extraction.14e17 However, even rarer, some patients may
spontaneously develop BRONJ in the absence of overt trauma or
dental extraction.18
The American Association of Oral and Maxillofacial Surgeons
has published the BRONJ diagnosis criteria in 2007,3 and thisreporting case was present with all three diagnostic elements of
BRONJ, i.e., (1) exposed bone being present for longer than eight
weeks, (2) exposure to bisphosphonates, and (3) no history of
radiation therapy to the maxilla or mandible. Although BRONJ is
rare and the BRONJ without preceding trauma is rarer, physicians
treating osteoporosis should bear in mind of this uncommon
complication. However, balancing the risks and beneﬁts of
bisphosphonate use, bisphosphonates are still considered safe in
clinical practice. The potential fracture risk secondary to the
discontinuation of bisphosphonates should be balanced by other
agents or treatment strategies. Collaboration with pharmacists in
clinical practice may be important to gain better insights into the
optimal treatment of patients with osteonecrosis of the jaws and
to promote early detection of BRONJ.
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